Amygdala Neurosciences

Executive Summary

Amygdala Neurosciences is a San Diego-based biopharmaceutical company dedicated to developing first-in-class medicines for substance use disorders (SUD), a chronic and recurring disease that affects millions worldwide. Founded in 2017, the company focuses on inhibiting aldehyde dehydrogenase 2 (ALDH2) to reduce cravings and prevent relapse in addiction. Their approach targets the underlying neurobiology of addiction, offering a novel mechanism distinct from existing treatments. By addressing the root cause of compulsive drug-seeking behavior, Amygdala aims to provide patients with a transformative therapy that could significantly improve outcomes in SUD management. The company's lead program is centered on small-molecule ALDH2 inhibitors, which have shown promise in preclinical models. While Amygdala remains private and has not disclosed specific financial or clinical milestones, the scientific rationale for targeting ALDH2 in addiction is supported by emerging research linking acetaldehyde metabolism to reward pathways. The company's progress will depend on advancing its candidate through IND-enabling studies and into clinical trials. If successful, Amygdala could become a pioneer in a new class of addiction therapies, addressing an urgent unmet need with a potentially high-impact solution. However, early-stage development and limited public information contribute to uncertainty around timelines and funding.

Upcoming Catalysts (preview)

• Q3 2026Completion of preclinical IND-enabling studies for lead ALDH2 inhibitor50% success
• Q4 2026Securing Series A financing to fund clinical development35% success
• TBDAnnouncement of partnership or licensing deal for SUD pipeline20% success